Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Elutia Inc ELUT

Healthcare Biotechnology
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use... see more

Recent & Breaking News (NDAQ:ELUT)

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

GlobeNewswire November 14, 2024

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

GlobeNewswire November 13, 2024

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

GlobeNewswire October 29, 2024

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

GlobeNewswire October 23, 2024

SWK Holdings Provides Portfolio Update

ACCESS Newswire October 17, 2024

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro(TM), Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

GlobeNewswire September 18, 2024

Elutia Celebrates First Year

GlobeNewswire September 6, 2024

Elutia Announces First Patient Implant of EluPro(TM), the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

GlobeNewswire September 5, 2024

Elutia to Participate in Upcoming Investor Conferences

GlobeNewswire September 3, 2024

Elutia Announces Second Quarter 2024 Results

GlobeNewswire August 7, 2024

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

GlobeNewswire August 1, 2024

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

GlobeNewswire July 31, 2024

Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

GlobeNewswire July 30, 2024

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

ACCESS Newswire July 17, 2024

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

GlobeNewswire July 11, 2024

Elutia Announces $13.26 Million Registered Direct Offering

GlobeNewswire June 17, 2024

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

GlobeNewswire June 17, 2024

Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024

GlobeNewswire May 13, 2024

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

GlobeNewswire May 9, 2024

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

GlobeNewswire May 2, 2024